Fairvalue-Calculator Fairvalue-Calculator
EN DE

H.U. Group (MRCHF) Fair Value & Analysis

Healthcare · US · Market cap $1.1B

Price$20.05
Fair Value$16.91
Upside-15.7%
Quality97/100
Evidence: High Range $12.68 – $21.14

Analysis

H.U. Group (MRCHF) currently trades at $20.05, while our model-based Fair Value estimate is $16.91 — implying the stock looks roughly 15.7% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment provides general testing services to medical institutions that include esoteric testing, such as genetic and oncology testing; companion diagnostics-related tests for cancer treatment; omics analysis comprising whole genome sequencing and proteome analysis; comprehensive support for clinical trials and research, including pre-trial setup work, specimen collection and transport, measuring, result reports, and data management, as well as SaaS for general practitioners and personal health records. Its In-Vitro Diagnostics segment provides Lumipulse system products, an automated chemiluminescence enzyme immunoassay system that offers reagents; testing services for neurodegenerative diseases; and rapid diagnostics kit for infectious diseases comprising influenza and COVID-19, as well as cerebrosp…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -60% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -54%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.